Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Oncimmune Holdings ( (GB:ONC) ) just unveiled an announcement.
Oncimmune Holdings plc has reported significant revenue growth, projecting approximately £3m for FY2024, more than doubling from the previous year. For FY2025, the company anticipates revenue of about £4m, representing a 33% increase over FY2024. Despite the slower conversion of new contracts, Oncimmune has secured new deals and is negotiating others, with a potential value of up to £2.0m. Strategic collaborations and business synergies are under exploration to boost its financial standing. The company has also reduced its overheads and debt service costs, ensuring a leaner cost base in FY2025.
More about Oncimmune Holdings
Oncimmune Holdings plc is a precision medicine company specializing in analyzing immune interactions through autoantibody profiling. They partner with global pharmaceutical and biotech companies to discover novel biomarkers and develop targeted therapies for immune-mediated diseases. Headquartered in the UK, with a facility in Germany and a business development team across the US and Europe, Oncimmune aims to enhance precision medicine through its scientific expertise and technology platform.
YTD Price Performance: -14.98%
Average Trading Volume: 214,498
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £13.64M
For a thorough assessment of ONC stock, go to TipRanks’ Stock Analysis page.
